[COVID-19 and stress-related disorders]. / Kovid-19 i stress-svyazannye rasstroistva.
Zh Nevrol Psikhiatr Im S S Korsakova
; 121(5. Vyp. 2): 122-128, 2021.
Article
in Russian
| MEDLINE | ID: covidwho-1362772
ABSTRACT
Since the WHO declared the COVID-19 outbreak a pandemic, the most actual problem has been a change in the lifestyle of the population of Russia and the rest of the world. Fear of illness, self-isolation/quarantine, and decreased quality of life have dramatically increased the level of stress-related disorders in the population. The main mental disorders arising from stress refer to anxiety disorders (post-traumatic stress disorder (PTSD), panic disorder, agoraphobia, social phobia, generalized anxiety disorder), obsessive-compulsive disorder, depressions of varying severity and conversion reactions. The symptoms and early warning signs of stress-related disorders may be chronic or episodic. Stress-related disorders are corrected with psychotropic therapy, which aims to restore the balance of neurotransmitters. Current first choice agents for the treatment of both pathological anxiety and depression are selective serotonin reuptake inhibitors (SSRIs). During the pandemic, the SSRI fluvoxamine is of special interest. Its mechanisms of action are recognized as potentially useful for treating COVID-19 infection. Two studies confirming the efficacy and safety of fluvoxamine in the treatment of coronavirus infection are described.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Stress Disorders, Post-Traumatic
/
COVID-19
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
Russian
Journal:
Zh Nevrol Psikhiatr Im S S Korsakova
Journal subject:
Neurology
/
Psychiatry
Year:
2021
Document Type:
Article
Affiliation country:
Jnevro2021121052122
Similar
MEDLINE
...
LILACS
LIS